Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Cyclophosphamide and Filgrastim Followed By Stem Cell Transplant in Treating Patients With Chronic or Accelerated Phase Myelogenous Leukemia
This study has been terminated.
( Study terminated as principal investigator [PI] left the university. )
Study NCT00005984 Information provided by National Cancer Institute (NCI)
First Received: July 5, 2000 Last Updated: August 9, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cyclophosphamide
filgrastim
recombinant interferon alfa
radiation therapy
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Masonic Cancer Center, University of Minnesota
Back to top of Main Content
